19 results about "Medication abuse" patented technology

In one aspect, a sensor for detecting a drug of abuse (DOA) in a sample is disclosed. In some embodiments, the sensor includes a graphene layer, a plurality of binding agents, which bind to the DOA, coupled to said graphene layer to generate a functionalized graphene layer, and a plurality of electrical conductors electrically coupled to said functionalized graphene layer for measuring an electrical property of said functionalized graphene layer. While in some embodiments, such binding agents are monoclonal antibodies, in other embodiments they are polyclonal antibodies.

The disclosure is directed at an abuse-deterrent pharmaceutical composition comprising a coated antagonist particle, and the use thereof for preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering. Methods for manufacturing such an abuse-deterrent pharmaceutical composition are also provided.

The present application relates to the field of immunochromatography, in particular to a sample pad treatment method, a detection method and a chromatography test paper for drug abuse detection, and discloses an immunochromatography test paper for drug abuse detection, which is characterized by a sample pad treatment liquid containing Pluronic F-127.

The present invention discloses a detection device, which includes a cup body. A first channel is provided in the cup body. The first channel includes a sample inlet and two sample outlets for sample outflow. Two separated chambers are also provided in the cup body, namely a first chamber and a second chamber. The first chamber is configured to receive and detect the sample flowing out from the sample outlet, and the second chamber is configured to receive the sample flowing out from the sample outlet. The first chamber and the second chamber can be closed and communicated with each other. The device of the present invention can not only instantaneously detect the abused drugs in the sample, but also collect and preserve the sample for secondary confirmation testing in the laboratory and / or for DNA testing to confirm whether there is drug abuse and to confirm the sample provider. The above-mentioned detected samples all come from the same sample, ensuring the accuracy of the results and reducing errors. Using this device for the detection of abused drugs is simple in operation and high in accuracy.

A value-based method of treating musculoskeletal pain is described, which includes care for the exacerbating coexisting physical and behavioral health concerns and the social determinants of health; all without bundling in surgery. In general, the techniques described may relate to a specific combination of treatment methodologies, including pain management, physical therapy, physical fitness and nutrition, weight management, behavioral health, substance abuse treatment, smoking cessation, reliable case management, and prompt referral for acute or severe pathological conditions.

A method of preparing an abuse deterrent pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. This produces an abuse deterrent pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.

Systems, methods, and computer program products are provided for detecting fluid flow through ultrasonic flow sensors and / or identifying medication diversion. An example system includes at least one processor configured to: generate, using at least one machine learning model, based on a time-series generated by an ultrasonic flow sensor, a predicted start time associated with a start of a flow, a predicted time period associated with the flow, and / or a predicted end time associated with an end of the flow; and / or identify, based on the time-series, in a database, at least one stored feature representation associated with at least one medication type.

Technologies and techniques for processing drug data in a computer network. Data from a prescription drug monitoring program (PDMP) and medical / prescription data is received for a patient. Image data of the one or more patients is also received from an image capturing device. The PDMP data, medical data and image data is processed to predictably determining a potential drug abuse condition in one of the one or more patients, wherein the predictive determination includes detecting one or more facial emotive expressions from the image data. A file including data relating to the drug abuse condition may be generated and transmitted to the computer network.

Compositions and methods are provided to determine occupancy level of opioid receptors in a subject. The disclosed methods may be performed non-invasively in the inner ear of the subject, and may be performed at a point-of-care location to provide guidance to a practitioner on tapering on pharmacotherapy or on a patient's risk of relapse for substance abuse.

A value-based method of treating musculoskeletal pain is described, which includes care for the exacerbating coexisting physical and behavioral health concerns and the social determinants of health; all without bundling in surgery. In general, the techniques described may relate to a specific combination of treatment methodologies, including pain management, physical therapy, physical fitness and nutrition, weight management, behavioral health, substance abuse treatment, smoking cessation, reliable case management, and prompt referral for acute or severe pathological conditions.

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

A precision dispensing device for liquids, including a device for remote control and monitoring. A dispensing device for liquids, more particularly pharmaceutical compositions, is described that allows remote control for all functions associated with dispensing the drug to the patient so as to prevent abuse. The dispensing device includes a contact or contactless reader, a GPS sensor, and a biometric sensor such as a fingerprint and facial recognition sensor. The dispensing device is connected to the Internet.

1. The name of the design product: drug screening reagent card. 2. The use of the design product: used for qualitative detection of specific drug components in human urine samples to screen for drug abuse. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: combination state diagram. 5. The design for which protection is sought contains color.

The present invention relates to compounds having pharmacological activity against the sigma (σ) receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, to methods of preparing such compounds, to pharmacological compositions comprising them and to their use in therapy, in particular against drug abuse and addiction.

The application relates to a computing device for identifying pharmacological phenotypes. Pharmacological phenotypes are predicted for patients who exhibit or are likely to exhibit a primary disease or complication. A machine learning engine may generate statistical models based on training data from a trained patient to predict pharmacological phenotypes, including drug responses and doses, drug adverse events, risk of diseases and complications, drug-gene interactions, drug-drug interactions, and multi-pharmacy interactions. The model can then predict the pharmacological phenotype of a new patient and can make decisions in clinical and research contexts, including drug selection and dosage, changes in drug treatment regimens, multi-pharmacy optimization, monitoring, and the like, to benefit from additional predictive capabilities, as well as to improve the ability to predict the pharmacological phenotype of the new patient. Therefore, adverse events and drug abuse are avoided, drug response is improved, patient recovery results are improved, treatment cost is reduced, public health benefits are improved, and research efficiency in pharmacology and other biomedical fields is improved.

Provided herein are pharmaceutical compositions comprising a denatonium salt and a pharmaceutical agent. Also provided herein are methods for reducing a risk of drug abuse comprising use of a denatonium salt to decrease the likelihood of improper ingestion of a pharmaceutical agent. Also provided herein are methods for making the test of a drug less palatable comprising a subclinical dose of a denatonium salt.

To provide a diversion detection system, a method, a device, and a storage medium for preventing diversion of a medicine.SOLUTION: A method for generating evidence of a diversion event includes detection of a trigger event in a medicine preparation cabinet including a medicine (702). The method includes activation of one or multiple monitoring devices so as to acquire a record according to detection of a trigger event (704). The record includes an event that is suspected of diversion. The method includes generation of one or multiple transaction records related to the record (706). The method includes filtering of multiple records on the basis of one or multiple transaction records in a database (712). The multiple records include a record for specifying whether an event suspected of diversion occurs. According to specification (714) of occurrence of an event suspected of diversion, the method includes generation of an alert showing occurrence of the event suspected of diversion (716).SELECTED DRAWING: Figure 7

The disclosure is directed at an abuse-deterrent pharmaceutical composition comprising a coated antagonist particle, and the use thereof for preventing or minimizing the risk of opioid abuse and / or opioid toxicity from either intentional or unintentional tampering. Methods for manufacturing such an abuse-deterrent pharmaceutical composition are also provided.

This invention relates to the pharmaceutical field, and particularly to the use of substances that specifically bind to S-100B protein in the preparation of diagnostic or prognostic products for acute retinal necrosis (ARN). By detecting the level of S-100B protein in the aqueous humor, the extent of optic nerve damage caused by ARN can be objectively and accurately observed. This can aid in the early clinical diagnosis of ARN, enabling timely and appropriate treatment, effectively reducing the risk of retinal detachment and blindness, and helping clinicians predict disease progression and visual prognosis, achieving early intervention, precision treatment, and reducing drug abuse and waste of medical resources.